Steve Hibbert
Overview
Explore the profile of Steve Hibbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
578
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene S, et al.
Lancet
. 2025 Feb;
405(10479):627-636.
PMID: 39919773
Background: GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk...
2.
Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, et al.
BMJ Open
. 2021 May;
11(5):e047993.
PMID: 34049922
Introduction: Parkinson's disease (PD) is a common neurodegenerative disorder with substantial morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 receptor agonist exenatide has been associated in single-centre studies...
3.
Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I, et al.
Eur J Neurosci
. 2018 Aug;
49(3):410-421.
PMID: 30070753
Exenatide, a glucagon-like peptide-1 agonist and a licensed treatment for Type 2 diabetes significantly reduced deterioration in motor symptoms in patients with Parkinson's disease in a randomized, placebo-controlled trial. In...
4.
Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene S, et al.
J Parkinsons Dis
. 2018 May;
8(2):247-258.
PMID: 29843254
Background: Exenatide is a GLP-1 receptor agonist that was recently studied for potential disease-modifying effects in a randomised, placebo-controlled clinical trial in patients with moderate stage Parkinson's disease, and showed...
5.
Athauda D, Maclagan K, Skene S, Bajwa-Joseph M, Letchford D, Chowdhury K, et al.
Lancet
. 2017 Aug;
390(10103):1664-1675.
PMID: 28781108
Background: Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. We investigated whether these effects would be apparent in a clinical trial. Methods:...
6.
Chow E, Bernjak A, Williams S, Fawdry R, Hibbert S, Freeman J, et al.
Diabetes
. 2014 Apr;
63(5):1738-47.
PMID: 24757202
Recent trials of intensive glycemic control suggest a possible link between hypoglycemia and excess cardiovascular mortality in patients with type 2 diabetes. Hypoglycemia might cause arrhythmias through effects on cardiac...
7.
Bown N, Cotterill S, Roberts P, Griffiths M, Larkins S, Hibbert S, et al.
Med Pediatr Oncol
. 2002 Feb;
38(1):11-21.
PMID: 11835232
Background: Tumor genetic features reported to correlate with adverse outcome in Wilms tumor include karyotype complexity, losses of material from the short arm of chromosome 1 and from the long...